Selected article for: "genome stability and high titer"
Author: Okeke, Malachy I.; Okoli, Arinze S.; Diaz, Diana; Offor, Collins; Oludotun, Taiwo G.; Tryland, Morten; Bøhn, Thomas; Moens, Ugo
Title: Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
  • Document date: 2017_10_29
    • ID: 175igdfk_28
    Snippet: Since MVA is subjected to selection pressure (multiple multiplication cycles) during production of a high titer virus stock intended for vaccination, it is essential to examine the genome stability of the virus across MSV + 1 to MSV + 5 in human cell lines and in immune-competent and immune-compromised animal models. At present, this information is not provided in ERA dossiers submitted for clinical trials or MAA because relevant EU directive (Di.....
    Document: Since MVA is subjected to selection pressure (multiple multiplication cycles) during production of a high titer virus stock intended for vaccination, it is essential to examine the genome stability of the virus across MSV + 1 to MSV + 5 in human cell lines and in immune-competent and immune-compromised animal models. At present, this information is not provided in ERA dossiers submitted for clinical trials or MAA because relevant EU directive (Directive 2001/18/EC) has not made the provision of such data obligatory. Data on evolution of MVA in permissive cells during Good Manufacturing Practice (GMP) manufacturing will enable risk assessors to evaluate the genome stability of MVA and the presence of variants in the production batch intended for vaccination. The emergence of quasi-species and their role in the modulation of the MVA phenotype including host range, infectivity, attenuation, virulence and biodistribution is an omitted research field that needs to be addressed.

    Search related documents:
    Co phrase search for related documents
    • address need and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • address need and high titer: 1
    • address need and host range: 1
    • address need and human cell: 1, 2, 3, 4, 5, 6, 7, 8
    • address need and human cell line: 1, 2, 3, 4
    • animal model and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • animal model and high titer: 1, 2, 3, 4, 5
    • animal model and high titer virus: 1, 2
    • animal model and host range: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • animal model and human cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • clinical trial and GMP manufacturing: 1, 2, 3
    • clinical trial and high titer: 1, 2, 3, 4
    • clinical trial and host range: 1
    • clinical trial and human cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • EC Directive relevant EU directive and EU directive: 1
    • EC Directive relevant EU directive and genome stability: 1
    • EC Directive relevant EU directive and GMP manufacturing: 1
    • EC Directive relevant EU directive and high titer: 1
    • EC Directive relevant EU directive and high titer virus: 1